Pretargeting methods and compounds

Details Pretargeting methods and compounds Pretargeting methods and compounds

2006-07-18

2006-07-18

Saunders, David (Department: 1644)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Coated, impregnated, or colloidal particulate

C424S009363, C424S009440, C540S474000, C548S303700, C548S304100

Reexamination Certificate

active

07078013

ABSTRACT:
Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

REFERENCES:
patent: 4639365 (1987-01-01), Sherry
patent: 4647447 (1987-03-01), Gries et al.
patent: 4833251 (1989-05-01), Musso et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4895955 (1990-01-01), Ford et al.
patent: 4898951 (1990-02-01), Symons
patent: 5141966 (1992-08-01), Porath
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5326778 (1994-07-01), Rosebrough
patent: 5482698 (1996-01-01), Griffiths
patent: 5525338 (1996-06-01), Goldenberg
patent: 5690907 (1997-11-01), Lanza
patent: 5736119 (1998-04-01), Goldenberg et al.
patent: 5807879 (1998-09-01), Rosebrough
patent: 5955605 (1999-09-01), Axworthy et al.
patent: 6022966 (2000-02-01), Gustavson et al.
patent: 6120768 (2000-09-01), Griffiths et al.
patent: 6709652 (2004-03-01), Reno et al.
patent: 251 494 (1988-01-01), None
patent: 327 365 (1989-08-01), None
patent: 451 824 (1991-10-01), None
patent: 496 074 (1992-07-01), None
patent: WO 88/08422 (1988-11-01), None
patent: WO 89/10140 (1989-11-01), None
patent: WO 90/12050 (1990-10-01), None
patent: WO 92/12730 (1992-08-01), None
patent: WO 93/15210 (1993-08-01), None
patent: WO 94/17829 (1994-08-01), None
Axworthy et al., “Antibody Pretargeting For Radioimmunotherapy: A Three-Step Approach In Tumored Nude Mice,”The Journal Of Nuclear Medicine; Proceedings Of The 39thAnnual Meeting 33: p. 880, Abstract No. 234, 1992.
Chatterjee,Cancer Immunol. Immunother. 38: 75-82, 1994.
Curti,Crit. Rev. Oncol./Hematol. 14: 29, 1993.
Galli et al., “A Radiopharmaceutical For The Study Of The Liver:99mTc-DTPA-ASIALO-OROSOMUCOID. II: Human Dynamic and Imaging Studies,”The Journal Of Nuclear Medicine And Allied Sciences 32: 117-126, 1988.
Goldberg, CA-A Cancer Journal for Clinicians, 44:43, 1994.
Goodwin et al., “Pharmacokinetics of Biotin-Chelate Conjugates for Pretargeted Avidin-biotin Immunoscintigraphy,”J. Nucl. Med.: p. 880, Abstract No. 232, 1992.
Goodwin, “New Methods for Localizing Infection: A role for Avidin-Biotin,?”J. Nucl. Med. 33(10): 1816-1818, 1992.
Goodwin/Hnatowich, Letter to the Editor/Reply,J. Nucl. Med. 32(4): 750-751, 1991.
Green, “The Use of [14C]Biotin for Kinetic Studies and for Assay,”Biochem. J. 89: 585, 1963.
Harris et al.,Tibtech 11: 42, 1993.
Hnatowich et al., “Investigations of Avidin and Biotin for Imaging Applications,”J. Nucl. Med. 28(8): 1294-1302, 1987.
Jain,Scientific American 271(1): 58, 1994.
Jokiranta et al., “Biotinylation of Monoclonal Antibodies Prevents Their Ability to Activate the Classical Pathway of Complement,”The Journal of Immunology 151(4): 1'14-2131, 1993.
Kalofonos et al., “Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated Antibodies: Preliminary Communication,”J. Nucl. Med. 31(11): 1791-1796, 1990.
Koch and Macke, “99m-Tc Labeled biotin conjugates in a Tumor “Pretargeting” Approach with Monoclonal Antibodies,”Angew. Chem. Intl. Ed. Engl. 31(11): 1507-1509, 1992.
Kricka et al., “Survey of Methods of Measuring Human Anti-Mouse Antibodies,” HAMA Survey Group,Clinica Chimica Acta. 215: 153-163, 1993.
McMurry et al., “Convenient Synthesis of Bifunctional Tetraaza Macrocycles,”Bioconjugate Chem. 3(2): 108-117, 1992.
Osband et al.,Immunol. Today 11: 193, 1990.
Paganelli et al., “Intraperitoneal Radio-Localization of Tumors Pre-Targeted by Biotinylated Monoclonal Antibodies,”Int. J. Cancer 45: 1184-1189, 1990.
Paganelli et al., “Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system,”Nuclear Medicine Communications 12: 211-234, 1991.
Renn and Meares, “Large-Scale Synthesis of Bifunctional Chelating Agent 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic Acid, and the Determination of Its Enantiomeric Purity by Chiral Chromatography,”Bioconjugate Chem. 3(6): 563-569, 1992.
Rosario et al., “Bolton-Hunter and Biotin Derivatized Polylysine: A New Multi-Valent Peptide Reagent forIn VivoPre-Targeting with Streptavidin Conjugates,”J. Nucl. Med. 32(5): p. 993, Abstract No. 356, 1991.
Rosebrough, “Plasma Stability and Pharmacokinetics of Radio-labeled Deferoxamine-Biotin derivatives,”J. Nucl. Med.: p. 880, Abstract No. 235, 1992.
Sanderson et al., “Preparation And Characterization Of Biotin conjugates Of Anti-Pan-Carcinoma NR-LU-10 Monoclonal Antibody For A Three Step radioimmunotherapy,”The Journal Of Nuclear Medicine; Proceedings Of The 39thAnnual Meeting 33: p. 880, Abstract No. 233, 1992.
Van der Sluijs et al., “Drug Targeting to the Liver with Lactosylated Albumins: Does the Glycoprotein Target the Drug of is the Drug Targeting the Glycoprotein,”Hepatology 6(4): 723-728, 1986.
Virzi et al., “New Indium-111 Labeled Biotin Derivatives for Improved Immunotargeting,”Nucl. Med. Biol. 18(7): 719-726, 1991.
Virzi et al., “The Preparation and Evaluation of 12 Biotin Derivatives labeled with Tc-99M,”J. Nucl. Med.: p. 920, Abstract No. 403, 1992.
Wolf et al.,Methy. Enzym. 184: 103, 1990.
Wu et al., “Investigations of N-Linked Macrocycles forI I IIn and90Y Labeling of Proteins,”Nucl. Med. Biol. Int. J. Radiat. Appl. Instrum. Part B 19(2): 239-244, 1992.
Zwierzina,StemCells 11: 144, 1993.

Affiliated with

Also associated with

Rating

Pretargeting methods and compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pretargeting methods and compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pretargeting methods and compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3581787